ぶどう膜炎の世界市場インサイト・疫学分析・市場予測

DelveInsightが発行した調査報告書(DELV803018)
◆英語タイトル:Uveitis Market Insight, Epidemiology and Market Forecast
◆商品コード:DELV803018
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2018年3月
◆ページ数:132
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2営業日以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD6,250 ⇒換算¥706,250見積依頼/購入/質問フォーム
Site Price(同一事業所内共有可)USD12,500 ⇒換算¥1,412,500見積依頼/購入/質問フォーム
Enterprise Price(同一法人内共有可)USD18,750 ⇒換算¥2,118,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

DelveInsight’s ‘Uveitis – Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Uveitis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Uveitis from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Uveitis – Disease Understanding and Treatment Algorithm
The DelveInsight Uveitis market report gives the thorough understanding of the Uveitis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Uveitis in the US, Europe, and Japan.

Uveitis Epidemiology
The Uveitis epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covers the prevalence of both Infectious and Non-Infectious Uveitis (NIU). Prevalence of NIU is further segmented into four types basis of sub-type [Intermediate Uveitis, Pan-Uveitis, Posterior Uveitis, Anterior noninfectious uveitis (aNIU] in 7MM.
According to DelveInsight, the prevalent cases of Uveitis was 706,666 in 2016 in 7 MM, of which 643,721 cases were of Non-Infectious Uveitis (NIU). As per DelveInsight estimation prevalent cases of Uveitis is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. United States account for highest prevalent cases of Uveitis with 392,035 prevalent cases in 2016 followed by France.

Uveitis Drug Chapters
This segment of the Uveitis report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The market of Uveitis is dominated with corticosteroids, immunosuppressants and biologics. Off-label corticosteroids, immunosuppressive and biologics are also being used for Uveitis. Corticosteroids are used as first line of therapy for treatment of Uveitis. Currently four corticosteroids namely Durezol, Retisert, Ozurdex and Triesence are being used. The first approved monoclonal antibody approved for the treatment of Uveitis was Humira (Adalimumab). This report includes detailed chapters of marketed along with the promising upcoming therapies.

Uveitis Market Outlook
The Uveitis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Uveitis market is expected to grow during the forecasted period of 2018-2027 at a CAGR of XX% owing to the launch of nine drugs (presently in Phase III). Uveitis Therapeutics market has seen a global sales of 5.4 billion in 2016. The three best selling drugs were Vimpat (UCB), Lamictal (Glaxosmithkline) and Keppra (UCB) with Vimpat recording highest sales of 895 million in 2016.

Uveitis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Uveitis Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Uveitis Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Uveitis Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Uveitis market
• Organize sales and marketing efforts by identifying the best opportunities for Uveitis market
• To understand the future market competition in the Uveitis market.

【レポートの目次】

1. Report Introduction 2
2. Uveitis Market Overview at a Glance 12
2.1. Total Market Share Distribution Of Uveitis For 7 MM In 2016 12
2.2. Total Market Share Distribution Of Uveitis For 7 Mmin 2025 12
3. Uveitis: Overview 13
3.1. Classification Of Uveitis 13
3.2. Pathophysiology 15
3.3. Symptoms Of Uveitis 16
3.4. Etiology Of Uveitis 16
3.5. Diagnosis Of Uveitis 17
3.6. Treatment Of Uveitis 18
4. Epidemiology and Patient Population 20
4.1. Key Points 20
4.1.1. Population And Forecast Parameters 21
4.1.2. Prevalent Population of Uveitis in 7MM 22
4.1.3. Region-Wise Prevalent Population Of Uveitis 23
4.1.4. Region-Wise Prevalent Population Of Non-Infectious Uveitis (NIU) 24
4.2. United States 25
4.2.1. Prevalent Population Of Uveitis 25
4.2.2. Sub-Type Specific Prevalent Population Of Noninfectious Uveitis (NIU) 27
4.3. Germany 28
4.3.1. Prevalent Population Of Uveitis 28
4.3.2. Sub-Type Specific Prevalent Population Of Noninfectious Uveitis (NIU) 30
4.4. France 31
4.4.1. Prevalent Population Of Uveitis 31
4.4.2. Sub-Type Specific Prevalent Population Of Noninfectious Uveitis (NIU) 33
4.5. Italy 34
4.5.1. Prevalent Population Of Uveitis 34
4.5.2. Sub-Type Specific Prevalent Population Of Noninfectious Uveitis (NIU) 36
4.6. Spain 37
4.6.1. Prevalent Population Of Uveitis 37
4.6.2. Sub-Type Specific Prevalent Population Of Noninfectious Uveitis (NIU) 39
4.7. United Kingdom 40
4.7.1. Prevalent Population Of Uveitis 40
4.7.2. Sub-Type Specific Prevalent Population Of Noninfectious Uveitis (NIU) 42
4.8. Japan 43
4.8.1. Prevalent Population Of Uveitis 43
4.8.2. Sub-Type Specific Prevalent Population Of Non-Infectious Uveitis (NIU) 45
5. Treatment Algorithm 46
5.1. First Line Of Therapy: Corticosteroids 51
5.2. Second Line Of Therapy: Immunosuppressants 52
5.3. Third Line Of Therapy: Biologics 54
6. Current Unmet Needs of Uveitis 56
7. Marketed Drugs 58
7.1. Durezol 59
7.1.1. Product Description 59
7.1.2. Regulatory Milestones 59
7.1.3. Advantages & Disadvantages 60
7.1.4. Product Profile 60
7.1.5. Safety And Efficacy 61
7.1.6. Side Effects 61
7.1.7. SWOT Analysis 62
7.2. Triesence 63
7.2.1. Product Description 63
7.2.2. Regulatory Milestones 63
7.2.3. Advantages & Disadvantages 63
7.2.4. Product Profile 64
7.2.5. Safety And Efficacy 64
7.2.6. Side Effects 64
7.2.7. SWOT Analysis 65
7.3. Retisert 66
7.3.1. Product Description 66
7.3.2. Regulatory Milestones 66
7.3.3. Advantages & Disadvantages 67
7.3.4. Product Profile 67
7.3.5. Safety 68
7.3.6. Efficacy 68
7.3.7. Side Effects 69
7.3.8. SWOT Analysis 70
7.4. Ozurdex 71
7.4.1. Product Description 71
7.4.2. Regulatory Milestones 71
7.4.3. Advantages & Disadvantages 71
7.4.4. Product Profile 72
7.4.5. Efficacy 72
7.4.6. Safety 73
7.4.7. Side Effects 74
7.4.8. SWOT Analysis 75
7.5. Humira 76
7.5.1. Product Description 76
7.5.2. Regulatory Milestones 76
7.5.3. Advantages & Disadvantages 77
7.5.4. Product Profile 77
7.5.5. Safety And Efficay 77
7.5.6. Side Effects 78
7.5.7. SWOT Analysis 79
8. Emerging Drugs Analysis 80
8.1. Phase III Drugs Analysis- Corticosteroids 80
8.2. Phase III Drugs Analysis-Immunosuppressants 81
8.3. Phase II Drugs Analysis-Biologics 82
8.4. Emerging Drugs: Phase III Therapeutics 83
8.4.1. ADX-102 83
8.4.1.1. Product Description 83
8.4.1.2. Clinical Development 83
8.4.1.3. Advantages & Disadvantages 83
8.4.1.4. Product Profile 84
8.4.1.5. Safety And Efficacy 84
8.4.1.6. Clinical Pipeline Activity 85
8.4.1.7. Ongoing Trials Information 86
8.4.1.8. Clinical Trial By Phase 87
8.4.1.9. SWOT Analysis 88
8.4.2. Durasert 89
8.4.2.1. Product Description 89
8.4.2.2. Clinical Development 89
8.4.2.3. Advantages & Disadvantages 91
8.4.2.4. Product Profile 91
8.4.2.5. Safety And Efficacy 91
8.4.2.6. Side Effects 92
8.4.2.7. Clinical Pipeline Activity 93
8.4.2.8. Ongoing Trials Information 94
8.4.2.9. Clinical Trial By Phase 95
8.4.2.10. SWOT Analysis 96
8.4.3. Sirolimus 97
8.4.3.1. Product Description 97
8.4.3.2. Regulatory Milestones 97
8.4.3.3. Clinical Development 98
8.4.3.4. Advantages & Disadvantages 98
8.4.3.5. Product Profile 98
8.4.3.6. Safety And Efficacy 98
8.4.3.7. Clinical Pipeline Activity 99
8.4.3.8. Ongoing Trials Information 100
8.4.3.9. Clinical Trial By Phase 101
8.4.3.10. SWOT Analysis 102
8.4.4. EGP-437 103
8.4.4.1. Product Descripion 103
8.4.4.2. Regulatory Milestones 103
8.4.4.3. Clinical Development 104
8.4.4.4. Advantages & Disadvantages 104
8.4.4.5. Product Profile 105
8.4.4.6. Safety And Efficacy 105
8.4.4.7. Side Effects 105
8.4.4.8. Clinical Pipeline Activity 106
8.4.4.9. Ongoing Trials Information 107
8.4.4.10. Clinical Trial By Phase 108
8.4.4.11. SWOT Analysis 109
8.5. Emerging Drugs: Phase II Therapeutics 110
8.5.1. Sarilumab 110
8.5.1.1. Product Description 110
8.5.1.2. Product Development Activities 110
8.5.1.3. Clinical Development 110
8.5.1.4. Advantages & Disadvantages 110
8.5.1.5. Product Profile 111
8.5.1.6. Safety And Efficacy 111
8.5.1.7. Clinical Pipeline Activity 112
8.5.1.8. Clinical Trial By Phase 113
9. Market Size of Uveitis in 7MM 114
9.1. 7 Major Market Outlook 114
9.2. Market Size Of Uveitis In 7MM 116
9.3. Region Wisemarket Size Of Uveitis 117
9.3.1. United States 118
9.3.1.1. Market Outlook 118
9.3.1.2. Market Size 119
9.3.2. EU5 120
9.3.2.1. Market Outlook 120
9.3.2.2. Germany Market Size 121
9.3.2.3. France Market Size 122
9.3.2.4. Italy Market Size 123
9.3.2.5. Spain Market Size 124
9.3.2.6. United Kingdommarket Size 125
9.3.3. Japan 126
9.3.3.1. Market Outlook 126
9.3.3.2. Market Size 127
10. Appendix 129
10.1. Report Methodology 129
11. Consulting Services 131
12. Disclaimer 132
13. About DelveInsight 132

Table 1: Total Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU)in 7 MM (2015-2025) 22
Table 2: Region-Wise Prevalent Population ofUveitis (2015-2025) 23
Table 3: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Table 4: Prevalent Population ofUveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Table 5: Sub-type Specific Prevalent Population ofUveitis in United States (2015-2025) 27
Table 6: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Germany (2015-2025) 29
Table 7: Sub-type Specific Prevalent Population of Uveitis in Germany (2015-2025) 30
Table 8: Prevalent Population ofUveitis& NIU in France (2015-2025) 32
Table 9: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in France (2015-2025) 33
Table 10: Prevalent Population ofUveitis&Noninfectious Uveitis (NIU)in Italy (2015-2025) 35
Table 11: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in Italy (2015-2025) 36
Table 12: Prevalent Population of Uveitis &Non-Infectious Uveitis (NIU) in Spain (2015-2025) 38
Table 13: Sub-type Specific Prevalent Population of Uveitis in Spain (2015-2025) 39
Table 14: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Table 15: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in United Kingdom (2015-2025) 42
Table 16: Prevalent Population ofUveitisand Non-Infectious Uveitis (NIU) in Japan (2015-2025) 44
Table 17: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Table 18: First Line of Therapy of the treatment of Uveitis, 2016 51
Table 19: Marketed Drugs for Uveitis 58
Table 20: Comparison of Phase-III drugs (Corticosteroids) 80
Table 21: Comparison of Phase-III drugs (Corticosteroids) 81
Table 22: Phase II Drugs Analysis- Biologics 82
Table 23:ADX-102, Clinical Trials by Zone, 2017 85
Table 24:Clinical Trials by Recruitment status, 2017 86
Table 25: Durasert, Clinical Trials by Zone, 2017 93
Table 26: Clinical Trials by Recruitment status, 2017 94
Table 27:Sirolimus, Clinical Trials by Zone, 2017 99
Table 28:Clinical Trials by Recruitment status, 2016 100
Table 29:EGP-437, Clinical Trials by Zone, 2017 106
Table 30 :Clinical Trials by Recruitment status, 2017 107
Table 31:Sarilumab, Clinical Trials by Zone, 2017 112
Table 32: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Table 33: Market size of Uveitis by Region in USD Million (2015-2025) 117
Table 34: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Table 35: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Table 36: Market Size of Uveitis in France, USD Million (2015-2025) 122
Table 37: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Table 38: Market Size of Uveitis in Spain ,USD Million (2015-2025) 124
Table 39: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Table 40: Market Size of Uveitis in Japan, USD Million (2015-2025) 127


Figure 1: Classification of Uveitis 14
Figure 2: Diagnosis algorithm for Uveitis 17
Figure 3: Treatment Regimens 18
Figure 4: Total Prevalent Population OfUveitis&Non-Infectious Uveitis (NIU) in 7 MM (2015-2025) 22
Figure 5: Region-Wise Prevalent Population of Uveitis(2015-2025) 23
Figure 6: Region-Wise Prevalent Population of Non-Infectious Uveitis (NIU) (2015-2025) 24
Figure 7: Prevalent Population of Uveitis&Non-Infectious Uveitis (NIU) in United States (2015-2025) 26
Figure 8: Sub-type Specific Prevalent Population ofNon-infectious Uveitis (NIU) in United States (2015-2025) 27
Figure 9: Prevalent Population of Uveitis&Noninfectious Uveitis (NIU) in Germany (2015-2025) 29
Figure 10: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Germany (2015-2025) 30
Figure 11: Prevalent Population of Uveitis& NIU in France (2015-2025) 32
Figure 12: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU) in France (2015-2025) 33
Figure 13: Prevalent Population of Uveitis &Noninfectious Uveitis (NIU) in Italy (2015-2025) 35
Figure 14: Sub-type Specific Prevalent Population of Noninfectious Uveitis (NIU)in Italy (2015-2025) 36
Figure 15: Prevalent Population ofUveitis &Non-Infectious Uveitis (NIU)in Spain (2015-2025) 38
Figure 16: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Spain (2015-2025) 39
Figure 17: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 41
Figure 18: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU)in United Kingdom (2015-2025) 42
Figure 19: Prevalent Population of Uveitis and Non-Infectious Uveitis (NIU)in Japan (2015-2025) 44
Figure 20: Sub-type Specific Prevalent Population of Non-Infectious Uveitis (NIU) in Japan (2015-2025) 45
Figure 21: Treatment Algorithm of Uveitis 47
Figure 22: ADX-102 , Clinical Trials by Zone (%), 2017 85
Figure 23: ADX-102 , Clinical Trials by Recruitment status (%), 2017 86
Figure 24: Durasert, Clinical Trials by Zone (%), 2017 93
Figure 25: Durasert Clinical Trials by Recruitment status (%), 2017 94
Figure 26: Sirolimus, Clinical Trials by Zone (%), 2017 99
Figure 27:Sirolimus, Clinical Trials by Recruitment status (%), 2017 100
Figure 28: EGP-437, Clinical Trials by Zone (%), 2017 106
Figure 29: EGP-437, Clinical Trials by Recruitment status (%), 2017 107
Figure 30: Sarilumab, Clinical Trials by Zone (%), 2017 112
Figure 31: 7 Major Market Size of Uveitis in USD Million (2015-2025) 116
Figure 32: Market size of Uveitis by Region in USD Million (2015-2025) 117
Figure 33: Market Size of Uveitis in United States, USD Million (2015-2025) 119
Figure 34: Market Size of Uveitis in Germany, USD Million (2015-2025) 121
Figure 35: Market Size of Uveitis in France, USD Million (2015-2025) 122
Figure 36: Market Size of Uveitis in Italy, USD Million (2015-2025) 123
Figure 37: Market Size of Uveitis in Spain, USD Million (2015-2025) 124
Figure 38: Market Size of Uveitis in United Kingdom, USD Million (2015-2025) 125
Figure 39: Market Size of Uveitis in Japan, USD Million (2015-2025) 127


【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ ぶどう膜炎の世界市場インサイト・疫学分析・市場予測(Uveitis Market Insight, Epidemiology and Market Forecast )]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆